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DOES BALANCE BILLING RAISE THE CONCERNS ON EQUITY OF 
HEALTH UNDER A NATIONAL HEALTH INSURANCE PROGRAM IN 
TAIWAN?
Chen SC1, Yang YC2, Tang CH2, Chuang PY2, Hung ST2, Pan TJ3
1Taipei County Hospital, Taipei, Taiwan; 2Taipei Medical University, Taipei, Taiwan; 3Columbia 
University, New York, NY, USA
OBJECTIVES: Drug-eluting stents (DESs) have been considered to be generally supe-
rior to bare-metal stents (BMSs) for its lower rates of target-vessel revascularization. 
The National Health Insurance (NHI) started reimbursing BMSs in July 1999. But 
when it came to DESs, balanced-billing was employed to reimburse DESs under the 
pressure of NHI’s widening ﬁ nancial deﬁ cits. Patients who chose DESs would need to 
pay the differences between the price of DESs charged by providers and the fee sched-
ule of BMSs set by NHI. Whether distribution of DESs would concentrate in patients 
with higher socioeconomic status remained an unanswered research question. This 
study aimed to examine the inﬂ uence of socioeconomic factors on the choice between 
DESs and BMSs in Taiwan. METHODS: Patients who admitted in the hospitals for 
coronary stenting during December 1, 2006 to December 31, 2007 in the Taiwan 
National Health Insurance (NHI) claims database were identiﬁ ed as the study cases. 
The Cox proportional hazard model was preformed to evaluate the relationship 
between socioeconomic factors and the likelihood of choosing DESs, controlling for 
other patients’ demographical factors and providers’ characteristics. RESULTS: There 
were 3773 cases of DESs and 7413 BMSs in the observation period. Patients who 
were with higher wage income level and residing in the northern part of Taiwan were 
signiﬁ cantly more likely to choose DESs. Veterans and patients from low-income 
households were signiﬁ cantly less likely to choose DESs. CONCLUSIONS: Socioeco-
nomic factors seemed to be strong predictors of choosing DESs. Future research on 
the implications of disparities in using DESs is warranted to evaluate the impact of 
the balance-bill on equity of health in Taiwan. 
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POTENTIAL DRUG–DRUG INTERACTIONS RELATED TO ANGIOTENSIN 
CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR 
BLOCKERS IN TAIWAN
Chang WY1, Chen LC1, Cheng LJ2
1Kaohsiung Medical University, Kaohsiung, Taiwan; 2University of Macau, Macau, Macau
OBJECTIVES: This study aims to evaluate potential drug-drug interactions (DDIs) 
related to angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor 
blockers (ARBs) in Taiwan. METHODS: This cross-sectional study used a claim-based 
dataset published by the Taiwanese National Health Research Institute, constituting 
of data for 1,000,000 beneﬁ ciaries randomly sampled in 2005 from the nationwide 
population and followed longitudinally from 1995 to 2008. Individual prescription 
data of hypertensive outpatients using ACEIs or ARBs were extracted from 2006 to 
2008. Level-1 to Level-3 potential DDIs were identiﬁ ed as the presence of interacting 
pairs deﬁ ned by the “Drug Facts and Comparisons.” Demographic of patients having 
potential DDIs, prescription details and prescription overlapping days (POD) were 
collected and presented in descriptive statistics. Frequency of potential DDIs was 
stratiﬁ ed by three age bands and four POD ranges and evaluated by Wald chi-square 
tests. RESULTS: Of all, 23,299 DDI prescriptions were assessed, including 22,967 
(98.58%) and 332 (1.42%) for ACEIs and ARBs. For ACEIs, the most common drug 
for potential Level-1 to Level-3 DDIs is amiloride (n = 3902, 16.99%), indomethacin 
(n = 624, 2.72%) and furosemide (n = 13137, 57.20%), respectively. For ARBs, the 
most frequent combined drug with Level-2 and Level-3 DDIs is lithium (n = 98, 
29.52%) and indomethacin (n = 234, 70.48%). The majority of patients who had 
used DDI prescriptions aged over than 45 years (in the age bands of “45–65 years” 
and “over 65 year”), and the most frequent POD range for DDI prescriptions is during 
16 to 30 days. CONCLUSIONS: Although there is only a small proportion of poten-
tial ACEIs/ARBs related DDI prescriptions in Taiwan, prescriptions are mostly pre-
scribed for mid-age and elderly patients and frequently continued for 1 month. Further 
study will still need to explore the association between potential DDI prescriptions 
and adverse outcomes to justify the appropriateness of these prescriptions. 
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PRESCRIPTION PATTERN OF DUAL ANTIPLATELET THERAPY AMONG 
TAIWANESE OLDER ADULTS
Yu IW1, Lin HW2
1China Medical University Hospital, Taichung, Taiwan; 2China Medical University, Taichung, 
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OBJECTIVES: Upon the coverage restriction proposed by Taiwan National Health 
Insurance (NHI), the dual antiplatelet therapy (DAT) with clopidogrel and aspirin 
could be reimbursed up to 9 months for some speciﬁ c indications since 2004. The 
longer duration of DAT was allowed for the cases with drug eluting stent (DES) since 
late 2006. Although evidence showed its risks outweighed the beneﬁ ts comparing to 
use aspirin alone, it is a lack of study examining the population use of DAT in Taiwan. 
A secondary data analysis was performed to examine the use patterns of DAT, speciﬁ -
cally among the older adults in Taiwan. METHODS: A population-based longitudinal 
assessment was conducted using the 2003–2007 NHI databases. Those beneﬁ ciaries 
in 60 years old of age and greater during the study period were evaluated. All relevant 
data, including visits toward physician clinics, outpatient departments, use of medica-
tions, and pertinent covered cost in the datasets of ambulatory care were retrieved 
and analyzed. Descriptive analysis was performed to describe the utilization and 
duration of DAT. RESULTS: Of 1 million beneﬁ ciaries being evaluated, 1511 older 
patients (age = 70.8 ± 8.0-year-olds) were prescribed DAT. A sharply increasing 
prescription of DAT occurred in 2007. 85.6% were prescribed with approval indica-
tions (i.e., ischemic heart diseases) for aspirin or clopidogrel alone. Thirty-one percent 
possessed with at least one atherothrombotic risk factors (DM, dyslipidemia), which 
might attribute to DAT. The duration of DAT was up to 13 months. About 10% had 
DAT for more than 9 months. CONCLUSIONS: A sharply increasing utilization of 
DAT among Taiwanese older adults occurred in 2007. The change of reimbursement 
policy for DES in Taiwan may be the major contributing factor. However, further 
studies are needed to explore other contributing factors of DAT and its effectiveness 
and safety outcomes. 
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POTENTIAL FOR PATIENT CONFUSION FROM BRAND SUBSTITUTION 
OF STATINS IN AUSTRALIA
Ortiz MS1, Calcino G2
1University of NSW, Darlinghurst, NSW, Australia; 2HI Connections, Canberra, ACT, Australia
OBJECTIVES: To study the extent of brand substitution and brand switching between 
statins available on the Australian Pharmaceutical Beneﬁ t Scheme (PBS). METHODS: 
PBS prescription claims provided by Medicare Australia of a 10% random sample of 
all Australian long-term concession card holders were assessed over the time period 
August 2007 through July 2008. Patients had to ﬁ ll at least four prescriptions for a 
statin with generics (simvastatin [ﬁ ve strengths with up to 17 brands], or pravastatin 
[four strengths with up to 12 brands]) over the 1-year period. The proportion of 
non-switchers (single brand only) and multiple switchers (two or more switches 
between brands) were determined for each strength of these statins. RESULTS: A total 
of 39,913 patients ﬁ lled at least four prescriptions for a statin in the time window. 
The majority of Concessional patients received a single brand over the period (simv-
astatin at 60% and pravastatin at 56%). A smaller proportion received three or more 
brands: 14% for simvastatin to 13% for pravastatin. The proportion of statin scripts 
for the originator brand ranged from 22% for Zocor (simvastatin) to 36% for Prava-
chol (pravastatin). A substantial proportion of statin patients were multiple switchers: 
23% for simvastatin and 25% for pravastatin. Neither the number of brands received 
nor the number of switches seemed to be affected by the number of brands available 
on the PBS. Multiple switching was more common in of those under 50 years (33%) 
compared with of those aged 70–79 years (23%). CONCLUSIONS: There is potential 
for patient confusion since there are multiple switches of both statins occurring in one 
quarter of these Australian statin patients. There was also a 43% increase in multiple 
switching by younger patients. 
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UTILIZATION, PRICE, AND EXPENDITURE TRENDS FOR ANGIOTENSIN 
RECEPTOR BLOCKERS IN THE MEDICAID PROGRAM
Bian B, Guo JJ, Kelton C, Wigle P
University of Cincinnati College of Pharmacy, Cincinnati, OH, USA
OBJECTIVES: Angiotensin receptor blockers (ARBs) have been widely prescribed for 
multiple indications, ranging from heart failure to the prevention of kidney disease in 
patients with diabetes mellitus. The purpose of this study was to describe the utiliza-
tion, price and expenditure trends of ARBs. METHODS: A retrospective, descriptive 
time-series analysis was performed using the National Medicaid pharmacy claims 
database from 1991 to 2008. The quarterly prescription numbers and reimbursement 
amounts were calculated over time by summing data for individual drug products. 
The quarterly per-prescription reimbursement as a proxy for drug price was computed 
for the price of ARBs. RESULTS: ARB prescriptions increased from 0.03 million in 
1995 to 7.8 million in 2005, representing a 259-fold increase. For individual drugs, 
the two top selling drugs were Diovan® and Cozaar®, with 867,840 prescriptions 
and 340,101 prescriptions, respectively. In 2006, ARB prescriptions dropped due to 
the implementation of Medicare Part D. Just 2 years later, only 2.1 million were 
prescribed. Expenditure for ARBs increased from $1.3 million in 1995 to $515 million 
in 2005, and dropped to $174 million in 2008. Medicaid expenditure for ARBs 
reached the summit in 2005 quarter 4, which was almost $60 million. But after 
Medicare Part D was implemented, payment dropped until 2007 quarter 3 and started 
to increase to 23 million by the end of study period at 2008 quarter 4. The average 
payment per ARB prescription also increased from 36.22 in 1995 to 81.84 in 2008. 
CONCLUSIONS: Dramatically increased utilization of ARBs was observed from this 
study due to their wide therapeutic indications and efﬁ cacy. A signiﬁ cant drop in 
utilization occurred from 2006–2008 and was related to the introduction of Medicare 
Part D. Regardless of the entry of new drugs in the same pharmacologic category, the 
payment per prescription continued to rise during the study period. 
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DOSE STATIN USE IN PATIENTS WITH DIABETES SAVE 
DOWNSTREAM RESOURCE UTILIZATION? A DIFFERENCE-IN-
DIFFERENCES ANALYSIS
Seetasith A, Zhang J
Virginia Commonwealth University, Richmond, VA, USA
OBJECTIVES: Diabetes affects 7.8% of the US population and is one of the most 
expensive medical conditions. The economic impact of statins, one of most effective 
cholesterol-lowering agents used today, is unclear. We sought to assess the impact of 
statin use on resource utilization among diabetes patients in the United States using 
a difference-in-differences analysis. METHODS: We identiﬁ ed and linked 858 
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community-dwelling patients with diabetes aged between 20 and 85 in the 2006 and 
2007 Medical Expenditure Panel Survey (MEPS) consolidated data ﬁ les, a nationally 
representative survey linked to prescribed medicines ﬁ le. The main outcome measure 
was the total expenditures including inpatient and ambulatory care, excluding phar-
macy costs, in 2006 and 2007, respectively. The differences in the health-care costs 
between statin users and nousers were estimated from the interaction terms between 
time trend and statin use, using a generalized linear model with a log link and gamma 
distribution, controlling for the difference in the two groups and time trend. The other 
covariates included were socioeconomic variables, insurance status, and comorbid 
conditions. RESULTS: In 2006, the median total expenditures of the statin users and 
nonusers were $1787 (IQR $583–5993) and $1117 (IQR $215–5565), respectively. 
In the subsequent year, the median total expenditures of the statin users and nonusers 
were $1452 (IQR $443–6354) and $851 (IQR $180–4451), respectively. No statisti-
cally difference in the total expenditures between the two groups was found (param-
eter estimate 0.37, 95% CI −0.05, 0.79, P-value 0.086). CONCLUSIONS: No 
evidence supporting the reduction in health-care resource utilization following statin 
use was found. While our ﬁ nding shows that statin use did not lower subsequent 
health-care resource utilization, further research is needed to investigate the potential 
effect of the differences among the users and nonusers, and the potential effect of the 
differential slopes of the two groups on resource utilization overtime. 
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WHICH STRATEGY CAN CONTROL THE EXPENDITURE OF 
HIGH-PRICE DRUGS?
Sooksriwong CO
Mahidol University, Bangkok, Thailand
OBJECTIVES: To compare patients’ expenditure on utilization of high price new 
statin drugs. METHODS: This is a cross-sectional analysis. The hospital database of 
out-patients diagnosed as hyperlipidemia during 2003–2006 was retrieved for drug 
names and their costs. The expenditure for statin drugs per patient before and after 
a new statin was prescribed were compared. RESULTS: Before Fluvastatin 80 mg was 
included to the hospital formulary in 2003, the expenditure for statin drugs per patient 
was 8.27 USD. Average statins expenditure after 3 months of Fluvastatin 80 mg ﬁ rst 
prescribed was increased to be was 22.59 USD or 273%, with the market share only 
0.4% of all antihyperlipidemic drugs prescribed in the hospital. When other statins, 
Pravastatin 40 mg, Atorvastatin 40 mg, Simvastatin 80 mg, Rosuvastatin 10 mg, and 
Pravastatin 20 mg; were included to a hospital formulary, the expenditure for statin 
drugs per patient were changed to +7%, +151%, −24%, +169, and −26%, respec-
tively; while the market share for each drug at the time of ﬁ rst prescribe was 1.9%, 
0.4%, 0.2%, 2.8%, and 1.0% respectively. It was found that when a new statin with 
the same generic name but different strength was prescribed, the average statin expen-
diture was reduced; while new generic statins increased the expenditure. The average 
cost of statins per patient after including Pravastatin 20 mg to the formulary in 2006 
was US$45.02; which was 544% of the baseline statins cost in 2003. CONCLU-
SIONS: The hospital administrator should employ effective strategies to control uti-
lization of high price drugs; also prevent excessive drug promotion. 
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ANTI-THROMBOLYTIC AGENT USE AND PATTERNS OF HEALTH-CARE 
UTILIZATION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION 
(AMI) USING KOREA NATIONAL HEALTH INSURANCE CLAIMS 
DATABASE
Choi J1, Jang EJ1, Suh HS1, Song H1, Choi DH2, Kim JS2, Lee SM1
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea; 
2Yonsei University College of Medicine, Seoul, South Korea
OBJECTIVES: To the estimate the health-care utilization patterns and costs related 
to ST-elevation acute myocardial infarction(STEMI) and understand the pattern of 
anti-thrombolytic use after stenting with a Korean population based design. 
METHODS: We extracted the insurance claims records of STEMI patients deﬁ ned as 
diagnosed with AMI and admitted by emergency room from Korea National Health 
Insurance claims database. We examined the health-care service provided to stent naïve 
patients among STEMI patients deﬁ ned as having no coronary-stents during one-year 
washout-period and having stents during two-year intake-period (January 1, 2006–
December 31, 2007). Annual claims records were aggregated for each patient to produce 
patient-speciﬁ c information on total utilization, costs and anti-thrombolytic use. We 
examined the pattern of anti-thrombolytic use according to types of the ﬁ rst stents(group 
I as using drug-eluting stents [DES], group II as using bare-metal stents [BMS]) and types 
of revascularization method (group A-DES, group B-BMS, group C-balloon, group 
D-CABG). RESULTS: There were 19,120 subjects identiﬁ ed as STEMI patients. Each 
STEMI patient had 8.7 outpatient visits, 1.1 admission per year. The total costs for 
treating STEMI in the nation was estimated as Korean-won (KRW)106,666million. 
The per-capita insurance-covered costs were KRW3,721,390. Those increased until 
the age of 74 years and reduced after the age of 75 years. The annual number of claims 
in tertiary hospital was slightly fewer than secondary hospitals (13,303 vs. 13,730), 
but insurance-covered costs/claim in tertiary hospital were higher than those in second-
ary hospitals by KRW1,493,051. The duration of using Cilostazol from the ﬁ rst 
stenting to revascularization in group I was 79.12 days, while GroupII was 73.44 
days. The use of Cilostazol was longer in group IA (95.8 days) or IC (89.18 days) 
than group IIA (62.15 days) or group IIC (61.33 days). CONCLUSIONS: In Korea, 
the burden of illness for AMI is a signiﬁ cant issue. Cilostazol was used longer when 
DES were used at ﬁ rst stenting compared to BMS. Whether the longer usage of Cilo-
stazol results in better outcome needs further research. 
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CLINICAL OUTCOMES FROM PHARMACIST-MANAGED 
ANTICOAGULATION CLINICS (ACC) IN PRIMARY CARE SETTINGS IN 
SINGAPORE
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Singapore; 3National Healthcare Group Pharmacy, Singapore
OBJECTIVES: Pharmacist-managed anticoagulation clinics (ACC) have been proven 
to provide positive outcomes in both overseas and local tertiary settings as part of a 
health-care team in caring for patients on warfarin therapy. However, currently, there 
is no published study on the effectiveness of pharmacist-managed ACC in the primary 
care settings in Singapore. Therefore, the primary objectives of this study were to 
determine the effectiveness of pharmacist-managed ACC in maintaining INR within 
the therapeutic range, and their associations with patient demographics. The second-
ary objective was to examine the incidence of warfarin-related adverse effects. 
METHODS: This was a retrospective, time-series study conducted in nine outpatient 
primary care clinics in Singapore from September to December 2009. All patients aged 
≥21 years with at least three visits with the ACC pharmacists within the ﬁ rst 12 months 
of physician referral were included in this study. Patient demographics and clinical 
outcomes, such as INR and incidence of warfarin-related adverse events, were col-
lected at ﬁ rst visit to ACC and at every 4-month interval for a total of 12 months. 
RESULTS: A total of 269 patients were under the care of ACC pharmacists from April 
2008 to May 2009, and of which 82 (30%) met the inclusion criteria. INR was 
maintained at therapeutic range throughout the 12-month period with minimal ﬂ uc-
tuations between each visit (P = 0.621). There was no association between INR and 
patient demographics except for intake of vitamins, supplements and herbal medica-
tions (P = 0.006) and change in medications (P = 0.039) at the 12th month. Docu-
mented warfarin-related adverse events included gingival bleeds (1; 1%), leg cramps 
(5; 6%), and swells (5; 6%). CONCLUSIONS: Pharmacist-managed ACC in the 
primary care settings in Singapore were effective in maintaining INR within the thera-
peutic range. The service also minimized the frequency of adverse events commonly 
associated with warfarin therapy. 
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PHYSICIAN-LEVEL CLASS EFFECT ON 90-DAY BLOOD PRESSURE 
VALUES: A META-ANALYSIS OF MULTILEVEL OBSERVATIONAL STUDIES 
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OBJECTIVES: Blood pressure (BP) values in response to antihypertensive treatment 
are inﬂ uenced by both physician- and patient-level factors. We quantiﬁ ed summary 
estimates of variability in BP values attributable to a physician-level class effect across 
six observational studies. METHODS: We evaluated 90-day BP data on 14,116 
patients, in whom prior treatment failed or was not tolerated, who received valsartan-
based therapy for the treatment of hypertension. Data were collected during six 
consecutive prospective, observational, multi-center, pharmaco-epidemiologic studies 
conducted in Belgium between 2005 and 2009. Each study was designed to collect 
data from patients and their treating physicians. We applied a two-level hierarchical 
linear modeling method, using mixed-effects regression with residual maximum likeli-
hood estimation. From these data, intraclass correlation coefﬁ cients (ICC)s were 
calculated to quantify the variability in 90-day systolic BP (SBP) and diastolic BP (DBP) 
values attributable to within-physician variability in each study. We then completed 
a random-effects meta-analysis of ICC point estimates and variance from each study, 
to account for within- and between-study differences, and derived ICC summary 
estimates and 95% conﬁ dence intervals (CI). RESULTS: Summary estimates of abso-
lute reduction in 90-day SBP and DBP across studies were −18.17 mmHg (95% CI = 
−16.84 to −19.51 mmHg) and −9.73 mmHg (95% CI = −9.22 to −10.24 mmHg) 
respectively. ICCs for SBP ranged from 0.210 to 0.277, with a random-effects 
summary estimate of 0.238 (95% CI = 0.220 to 0.256; P < 0.0001; = 0.002; I2 < 
1%). ICCs for DBP ranged from 0.176 to 0.282, with a random-effects summary 
estimate of 0.255 (95% CI = 0.229 to 0.282; P < 0.0001; = 0.022; I2 = 45.69%). 
CONCLUSIONS: Considering within- and between-study differences in ICC, the 
average proportion of variance in 90-day SBP and DBP values attributable to a phy-
sician-level class effect was between 22.0% and 25.6%, and 22.9% and 28.2%, 
respectively. Further research is warranted to identify speciﬁ c and amenable physician-
level factors that contribute to higher BP values in response to antihypertensive 
treatment. 
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ROLE OF COMMUNITY PHARMACISTS IN HEALTH-RELATED 
EDUCATION AND COUNSELLING: VIEWS FROM GENERAL PUBLIC IN 
THE STATE OF PENANG, MALAYSIA
Hassali MA, Haddad M, Shaﬁ e AA
Universiti Sains Malaysia, Minden, Penang, Malaysia
OBJECTIVES: To explore general public’s awareness and perceptions toward the role 
of community pharmacists in the provision of health related education and counsel-
